Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category, By Region, And Segment Forecasts, 2023 - 2030
This report can be delivered to the clients within 3 Business Days
Regenerative Medicine Market Growth & Trends
The global regenerative medicine market size is expected to reach USD 180.87 billion by 2030 expanding at a CAGR of 15.7% from 2023 to 2030, according to a new report by Grand View Research, Inc., The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.
Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.
Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson’s disease treatment. This approval was expected to expand the company’s offerings.
Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.
Regenerative Medicine Market Report Highlights
Regenerative Medicine Market Growth & Trends
The global regenerative medicine market size is expected to reach USD 180.87 billion by 2030 expanding at a CAGR of 15.7% from 2023 to 2030, according to a new report by Grand View Research, Inc., The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.
Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.
Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson’s disease treatment. This approval was expected to expand the company’s offerings.
Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.
Regenerative Medicine Market Report Highlights
- The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
- The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
- Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
- North America dominated the market in 2022 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
- Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
- By therapeutic category, the oncology segment dominated the segment in 2022 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth.
CHAPTER 1 EXECUTIVE SUMMARY
1.1 Market Outlook
1.2 Competitive Milieu
1.3 Segment Outlook
1.4 Market Summary
CHAPTER 2 RESEARCH METHODOLOGY
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Scope & Definition
2.3.1 Product
2.3.1.1 Therapeutics
2.3.1.2 Tools
2.3.1.3 Banks
2.3.1.4 Services
2.4 Market Model
2.4.1 Historic and base year estimates
2.4.2 Forecast analysis
CHAPTER 3 MARKET VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Market Dynamics
3.2.1 Market driver analysis
3.2.1.1 Presence of a strong pipeline and a large number of clinical trials
3.2.1.2 High economic impact of regenerative medicine
3.2.1.3 Emerging applications of gene therapy in regenerative medicine
3.2.1.4 Increasing government & private funding to support the development of regenerative medicine
3.2.1.5 Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
3.2.1.6 Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
3.2.1.7 Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
3.2.2 Market restraint analysis
3.2.3 High cost of treatment
3.2.3.1 Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
3.3.1 Market Challenge analysis
3.3.1.1 Current challenges of on-market gene therapies
3.4 Penetration & Growth Prospect Mapping for Therapeutic Category, 2022
3.5 Reimbursement Framework
3.5.1 Reimbursement Framework & Clinical Translation of RM
3.5.2 Reimbursement Framework for RM: Europe
3.5.3 Reimbursement Framework for RM: South Korea
3.6 Technology Overview
3.6.1 autologous cell transplantation
3.6.2 Next-generation cell-based therapies
3.6.3 CAR-T cell technologies
3.7 Cost Structure Analysis
3.8 User Perspective Analysis
3.8.1 Market influencer analysis
3.8.2 Consumer behavior analysis
3.9 Regenerative Medicine Market—SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.10 Industry Analysis – Porter’s
3.11 Regenerative Medicine Market Analysis Tools
3.11.1 Major deals & strategic alliances analysis
3.11.2 Merger & acquisition deals
3.11.3 Collaboration & partnerships
3.11.4 Business Expansion
3.11.5 Market entry strategies
3.11.5.1 Pharmaceutical and biotechnology companies
3.11.5.2 Raw material supplier
3.11.5.3 Contract Service Provider
3.11.5.4 Distributor
3.11.5.5 Companion Diagnostics companies:
3.11.6 Case studies
3.11.6.1 MACI (Vericel Corporation):
3.11.6.2 LAVIV (Azficel-T) (Fibrocell Technologies):
CHAPTER 5 COVID-19 IMPACT ANALYSIS
5.1 COVID-19 Impact Analysis
5.2 Challenges Analysis
5.2.1 Manufacturing & supply challenges
5.2.2 Other challenges
5.3 Opportunities analysis
5.3.1 Need for development of new therapies against SARS-CoV-2
5.3.1.1 T-cell Therapy
5.3.1.2 Cell Therapy
5.3.1.3 Gene Therapy
5.3.1.4 Tissue engineering
5.3.2 Rise in demand for supply chain management solutions
5.4 Challenges in Manufacturing T-cell Therapies Against COVID-19
5.5 Key Market Initiatives
5.6 Conclusion
CHAPTER 6 PRODUCT BUSINESS ANALYSIS
6.1 Regenerative Medicine Market: Product Movement Analysis
6.2 Therapeutics
6.2.1 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
6.2.2 Primary cell-based therapeutics
6.2.2.1 Global primary cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.2.2 Dermatology
6.2.2.2.1 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.2.3 Musculoskeletal
6.2.2.3.1 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.2.4 Surgical
6.2.2.4.1 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.2.5 Dental
6.2.2.5.1 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.2.6 Others
6.2.2.6.1 Global other primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.3 Stem cell & progenitor cell-based therapeutics
6.2.3.1 Global stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.3.2 Autologous
6.2.3.2.1 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.3.3 Allogeneic
6.2.3.3.1 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.3.4 Others
6.2.3.4.1 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.4 Cell-based immunotherapies
6.2.4.1 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
6.2.5 Gene therapies
6.2.5.1 Global gene therapies market, 2018 - 2030 (USD Million)
6.3 Tools
6.3.1 Global regenerative medicines tools market, 2018 - 2030 (USD Million)
6.4 Banks
6.4.1 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
6.5 Services
6.5.1 Global regenerative medicine services market, 2018 - 2030 (USD Million)
CHAPTER 7 THERAPEUTIC CATEGORY BUSINESS ANALYSIS
7.1 Regenerative Medicine Market: Therapeutic Category Movement Analysis
7.2 Dermatology
7.2.1 Global dermatological therapeutics market, 2018 - 2030 (USD Million)
7.3 Musculoskeletal
7.3.1 Global musculoskeletal therapeutics market, 2018 - 2030 (USD Million)
7.4 Immunology & Inflammation
7.4.1 Global immunology & inflammation therapeutics market, 2018 – 2030 (USD Million)
7.5 Oncology
7.5.1 Global oncology therapeutics market, 2018 - 2030 (USD Million)
7.6 Cardiovascular
7.6.1 Global cardiovascular therapeutics market, 2018 - 2030 (USD Million)
7.7 Ophthalmology
7.7.1 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
7.8 Others
7.8.1 Global other therapeutics market, 2018 - 2030 (USD Million)
CHAPTER 8. REGIONAL BUSINESS ANALYSIS
8.1. Regenerative Medicine Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. U.S. Regenerative Medicine Market, 2018 - 2030 (USD MILLION)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Reimbursement Scenario
8.2.4.6. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.4. U.K.
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. U.K. Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Reimbursement Scenario
8.3.10.6. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. Reimbursement Scenario
8.4.8.6. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Reimbursement Scenario
8.5.5.6. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Reimbursement Scenario
8.6.6.6. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Regenerative Medicine Market Share Analysis, 2022
9.3.3. Company Profiles
9.3.3.1. AstraZeneca plc
9.3.3.2. F. Hoffmann-La Roche Ltd.
9.3.3.3. Integra Lifesciences Corp.
9.3.3.4. Astellas Pharma, Inc.
9.3.3.5. Cook Biotech, Inc.
9.3.3.6. Bayer AG
9.3.3.7. Pfizer, Inc.
9.3.3.8. Merck KGaA
9.3.3.9. Abbott
9.3.3.10. Vericel Corp.
9.3.3.11. Novartis AG
9.3.3.12. GlaxoSmithKline (GSK)
9.3.3.13. Baxter International, Inc.
9.3.3.14. Boehringer Ingelheim
9.3.3.15. Amgen Inc.
9.3.3.16. Cesca Therapeutics, Inc.
9.3.3.17. U.S. Stem Cell, Inc.
9.3.3.18. Bristol-Myers Squibb
9.3.3.19. Eli Lilly and Company
9.3.3.20. NuVasive, Inc.
9.3.3.21. Organogenesis, Inc.
9.3.3.22. MiMedx Group, Inc.
9.3.3.23. Takara Bio, Inc.
9.3.3.24. Osiris Therapeutics, Inc.
9.3.3.25. Corline Biomedical AB
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Product/Service Launch
9.3.4.5. Partnerships
9.3.4.6. Others
1.1 Market Outlook
1.2 Competitive Milieu
1.3 Segment Outlook
1.4 Market Summary
CHAPTER 2 RESEARCH METHODOLOGY
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Scope & Definition
2.3.1 Product
2.3.1.1 Therapeutics
2.3.1.2 Tools
2.3.1.3 Banks
2.3.1.4 Services
2.4 Market Model
2.4.1 Historic and base year estimates
2.4.2 Forecast analysis
CHAPTER 3 MARKET VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Market Dynamics
3.2.1 Market driver analysis
3.2.1.1 Presence of a strong pipeline and a large number of clinical trials
3.2.1.2 High economic impact of regenerative medicine
3.2.1.3 Emerging applications of gene therapy in regenerative medicine
3.2.1.4 Increasing government & private funding to support the development of regenerative medicine
3.2.1.5 Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
3.2.1.6 Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
3.2.1.7 Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
3.2.2 Market restraint analysis
3.2.3 High cost of treatment
3.2.3.1 Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
3.3.1 Market Challenge analysis
3.3.1.1 Current challenges of on-market gene therapies
3.4 Penetration & Growth Prospect Mapping for Therapeutic Category, 2022
3.5 Reimbursement Framework
3.5.1 Reimbursement Framework & Clinical Translation of RM
3.5.2 Reimbursement Framework for RM: Europe
3.5.3 Reimbursement Framework for RM: South Korea
3.6 Technology Overview
3.6.1 autologous cell transplantation
3.6.2 Next-generation cell-based therapies
3.6.3 CAR-T cell technologies
3.7 Cost Structure Analysis
3.8 User Perspective Analysis
3.8.1 Market influencer analysis
3.8.2 Consumer behavior analysis
3.9 Regenerative Medicine Market—SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.10 Industry Analysis – Porter’s
3.11 Regenerative Medicine Market Analysis Tools
3.11.1 Major deals & strategic alliances analysis
3.11.2 Merger & acquisition deals
3.11.3 Collaboration & partnerships
3.11.4 Business Expansion
3.11.5 Market entry strategies
3.11.5.1 Pharmaceutical and biotechnology companies
3.11.5.2 Raw material supplier
3.11.5.3 Contract Service Provider
3.11.5.4 Distributor
3.11.5.5 Companion Diagnostics companies:
3.11.6 Case studies
3.11.6.1 MACI (Vericel Corporation):
3.11.6.2 LAVIV (Azficel-T) (Fibrocell Technologies):
CHAPTER 5 COVID-19 IMPACT ANALYSIS
5.1 COVID-19 Impact Analysis
5.2 Challenges Analysis
5.2.1 Manufacturing & supply challenges
5.2.2 Other challenges
5.3 Opportunities analysis
5.3.1 Need for development of new therapies against SARS-CoV-2
5.3.1.1 T-cell Therapy
5.3.1.2 Cell Therapy
5.3.1.3 Gene Therapy
5.3.1.4 Tissue engineering
5.3.2 Rise in demand for supply chain management solutions
5.4 Challenges in Manufacturing T-cell Therapies Against COVID-19
5.5 Key Market Initiatives
5.6 Conclusion
CHAPTER 6 PRODUCT BUSINESS ANALYSIS
6.1 Regenerative Medicine Market: Product Movement Analysis
6.2 Therapeutics
6.2.1 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
6.2.2 Primary cell-based therapeutics
6.2.2.1 Global primary cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.2.2 Dermatology
6.2.2.2.1 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.2.3 Musculoskeletal
6.2.2.3.1 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.2.4 Surgical
6.2.2.4.1 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.2.5 Dental
6.2.2.5.1 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.2.6 Others
6.2.2.6.1 Global other primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
6.2.3 Stem cell & progenitor cell-based therapeutics
6.2.3.1 Global stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.3.2 Autologous
6.2.3.2.1 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.3.3 Allogeneic
6.2.3.3.1 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.3.4 Others
6.2.3.4.1 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
6.2.4 Cell-based immunotherapies
6.2.4.1 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
6.2.5 Gene therapies
6.2.5.1 Global gene therapies market, 2018 - 2030 (USD Million)
6.3 Tools
6.3.1 Global regenerative medicines tools market, 2018 - 2030 (USD Million)
6.4 Banks
6.4.1 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
6.5 Services
6.5.1 Global regenerative medicine services market, 2018 - 2030 (USD Million)
CHAPTER 7 THERAPEUTIC CATEGORY BUSINESS ANALYSIS
7.1 Regenerative Medicine Market: Therapeutic Category Movement Analysis
7.2 Dermatology
7.2.1 Global dermatological therapeutics market, 2018 - 2030 (USD Million)
7.3 Musculoskeletal
7.3.1 Global musculoskeletal therapeutics market, 2018 - 2030 (USD Million)
7.4 Immunology & Inflammation
7.4.1 Global immunology & inflammation therapeutics market, 2018 – 2030 (USD Million)
7.5 Oncology
7.5.1 Global oncology therapeutics market, 2018 - 2030 (USD Million)
7.6 Cardiovascular
7.6.1 Global cardiovascular therapeutics market, 2018 - 2030 (USD Million)
7.7 Ophthalmology
7.7.1 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
7.8 Others
7.8.1 Global other therapeutics market, 2018 - 2030 (USD Million)
CHAPTER 8. REGIONAL BUSINESS ANALYSIS
8.1. Regenerative Medicine Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. U.S. Regenerative Medicine Market, 2018 - 2030 (USD MILLION)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Reimbursement Scenario
8.2.4.6. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.4. U.K.
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. U.K. Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Reimbursement Scenario
8.3.10.6. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. Reimbursement Scenario
8.4.8.6. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Reimbursement Scenario
8.5.5.6. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Reimbursement Scenario
8.6.6.6. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Regenerative Medicine Market Share Analysis, 2022
9.3.3. Company Profiles
9.3.3.1. AstraZeneca plc
9.3.3.2. F. Hoffmann-La Roche Ltd.
9.3.3.3. Integra Lifesciences Corp.
9.3.3.4. Astellas Pharma, Inc.
9.3.3.5. Cook Biotech, Inc.
9.3.3.6. Bayer AG
9.3.3.7. Pfizer, Inc.
9.3.3.8. Merck KGaA
9.3.3.9. Abbott
9.3.3.10. Vericel Corp.
9.3.3.11. Novartis AG
9.3.3.12. GlaxoSmithKline (GSK)
9.3.3.13. Baxter International, Inc.
9.3.3.14. Boehringer Ingelheim
9.3.3.15. Amgen Inc.
9.3.3.16. Cesca Therapeutics, Inc.
9.3.3.17. U.S. Stem Cell, Inc.
9.3.3.18. Bristol-Myers Squibb
9.3.3.19. Eli Lilly and Company
9.3.3.20. NuVasive, Inc.
9.3.3.21. Organogenesis, Inc.
9.3.3.22. MiMedx Group, Inc.
9.3.3.23. Takara Bio, Inc.
9.3.3.24. Osiris Therapeutics, Inc.
9.3.3.25. Corline Biomedical AB
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Product/Service Launch
9.3.4.5. Partnerships
9.3.4.6. Others
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 List of Secondary Sources
Table 4 List of Abbreviations
Table 5 Global Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 6 Global Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 7 Global Regenerative Medicine Market, by Region, 2018 - 2030 (USD Million)
Table 8 North America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 9 North America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 10 North America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 11 U.S. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 12 U.S. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 13 Canada Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 14 Canada Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 15 Europe Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 16 Europe Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 17 Europe Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 18 Germany Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 19 Germany Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 20 U.K. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 21 U.K. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 22 France Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 23 France Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 24 Italy Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 25 Italy Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 26 Spain Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 27 Spain Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 28 Denmark Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 29 Denmark Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 30 Norway Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 31 Norway Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 32 Sweden Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 33 Sweden Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 36 Asia Pacific Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 37 China Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 38 China Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 39 Japan Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 40 Japan Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 41 India Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 42 India Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 43 Australia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 44 Australia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 45 South Korea Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 46 South KoreaRegenerative Medicine Market, by services, 2018 - 2030 (USD Million)
Table 47 Thailand Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 48 Thailand Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
Table 49 Latin America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 50 Latin America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 51 Latin America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 52 Brazil Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 53 Brazil Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 54 Mexico Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 55 Mexico Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 56 Argentina Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 57 Argentina Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 59 Middle East & Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 60 Middle East & Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 61 South Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 62 South Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 63 Saudi Arabia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 64 Saudi Arabia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 65 UAE Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 66 UAE Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 67 Kuwait Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 68 Kuwait Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 List of Secondary Sources
Table 4 List of Abbreviations
Table 5 Global Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 6 Global Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 7 Global Regenerative Medicine Market, by Region, 2018 - 2030 (USD Million)
Table 8 North America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 9 North America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 10 North America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 11 U.S. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 12 U.S. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 13 Canada Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 14 Canada Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 15 Europe Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 16 Europe Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 17 Europe Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 18 Germany Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 19 Germany Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 20 U.K. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 21 U.K. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 22 France Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 23 France Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 24 Italy Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 25 Italy Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 26 Spain Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 27 Spain Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 28 Denmark Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 29 Denmark Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 30 Norway Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 31 Norway Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 32 Sweden Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 33 Sweden Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 36 Asia Pacific Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 37 China Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 38 China Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 39 Japan Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 40 Japan Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 41 India Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 42 India Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 43 Australia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 44 Australia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 45 South Korea Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 46 South KoreaRegenerative Medicine Market, by services, 2018 - 2030 (USD Million)
Table 47 Thailand Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 48 Thailand Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
Table 49 Latin America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 50 Latin America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 51 Latin America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 52 Brazil Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 53 Brazil Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 54 Mexico Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 55 Mexico Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 56 Argentina Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 57 Argentina Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 59 Middle East & Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 60 Middle East & Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 61 South Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 62 South Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 63 Saudi Arabia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 64 Saudi Arabia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 65 UAE Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 66 UAE Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 67 Kuwait Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 68 Kuwait Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market segmentation & scope
Fig. 2 Regenerative medicine market snapshot, USD Million, 2022
Fig. 3 Market research process
Fig. 4 Information procurement
Fig. 5 Primary research pattern
Fig. 6 Industry pyramid analysis
Fig. 7 Market research approaches
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD model assessment
Fig. 10 Primary research pattern
Fig. 11 Commodity flow analysis for historic and base year estimates
Fig. 12 Commodity flow analysis for forecast analysis
Fig. 13 Initiatives by Vericel Corporation to sustain market and boost revenue through its appr
Fig. 14 Regenerative medicines market: Ancillary market
Fig. 15 Regenerative medicine market driver impact
Fig. 16 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
Fig. 17 Number of gene therapies in clinical trials, 2020
Fig. 18 Number of ongoing clinical trials for regenerative medicine, 2019 & 2020
Fig. 19 Total global regenerative medicine financing, USD Billion, 2020
Fig. 20 Prevalence of chronic diseases in the U.S.
Fig. 21 Regenerative medicine market restraint impact
Fig. 22 Challenges in gene therapy arena by degree of difficulty to overcome
Fig. 23 Penetration & growth prospect mapping for therapeutic category, 2021
Fig. 24 Troubleshooting the challenges of implementing new reimbursement models pertaining to regenerative medicine
Fig. 25 Reimbursement models pertaining to regenerative medicine
Fig. 26 Operational entities associated with Alliance for regenerative medicine: Technology ove
Fig. 27 Inpatient vs. outpatient costs associated with CAR-T cell therapy
Fig. 28 Regenerative medicine: Market influencers
Fig. 29 SWOT analysis, by factor (Political & legal, economic, and technological)
Fig. 30 Porter’s Five Forces Analysis
Fig. 31 Strategy mapping
Fig. 32 Total M&A upfront payments in regenerative medicine space, by year
Fig. 33 Regenerative medicines market: Business model
Fig. 34 Registered cell therapy contract manufacturing organization (CMO) locations in the EU,
Fig. 35 Marketing channels
Fig. 36 Recent developments by key market participants
Fig. 37 Impact analysis of strategic moves employed by key market participants
Fig. 38 Company/competition categorization
Fig. 39 Key customers
Fig. 40 Key company market position analysis, 2022
Fig. 41 Top regional players: Regenerative medicine market
Fig. 42 Regenerative medicine market: Competitive dashboard analysis
Fig. 43 Regenerative medicine market: Product outlook and key takeaways
Fig. 44 Regenerative medicine market: Product movement analysis (USD Million)
Fig. 45 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
Fig. 46 Global primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 47 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 48 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 49 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 50 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 51 Global other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 52 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 53 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 54 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 55 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 56 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
Fig. 57 Global gene therapies market, 2018 - 2030 (USD Million)
Fig. 58 Global regenerative medicines tools, 2018 - 2030 (USD Million)
Fig. 59 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
Fig. 60 Global regenerative medicine services market, 2018 - 2030 (USD Million)
Fig. 61 Regenerative medicine market: Therapeutic category outlook and key takeaways
Fig. 62 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
Fig. 63 Global dermatological therapeutics category market, 2018 - 2030 (USD Million)
Fig. 64 Global musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
Fig. 65 Global immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
Fig. 66 Global oncology therapeutics category market, 2018 - 2030 (USD Million)
Fig. 67 Global cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
Fig. 68 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
Fig. 69 Global other therapeutics category market, 2018 - 2030 (USD Million)
Fig. 70 Regional outlook and key takeaways
Fig. 71 Regenerative medicine market: Regional movement analysis
Fig. 72 North America regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 U.S. regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Canada regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Europe regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Germany regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 U.K. regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 France regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Spain regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Italy regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Sweden regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Denmark regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Norway regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Asia-Pacific regenerative medicine market estimates and forecast, 2016-2027 (USD Millio
Fig. 85 Japan regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 China regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 India regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Australia regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 South Korea regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 Thailand regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Latin America regenerative medicine market estimates and forecast, 2016-2027 (USD Milli
Fig. 92 Brazil regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Mexico regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Argentina regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 MEA regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 96 South Africa regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Saudi Arabia regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 UAE regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Kuwait regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 1 Market segmentation & scope
Fig. 2 Regenerative medicine market snapshot, USD Million, 2022
Fig. 3 Market research process
Fig. 4 Information procurement
Fig. 5 Primary research pattern
Fig. 6 Industry pyramid analysis
Fig. 7 Market research approaches
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD model assessment
Fig. 10 Primary research pattern
Fig. 11 Commodity flow analysis for historic and base year estimates
Fig. 12 Commodity flow analysis for forecast analysis
Fig. 13 Initiatives by Vericel Corporation to sustain market and boost revenue through its appr
Fig. 14 Regenerative medicines market: Ancillary market
Fig. 15 Regenerative medicine market driver impact
Fig. 16 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
Fig. 17 Number of gene therapies in clinical trials, 2020
Fig. 18 Number of ongoing clinical trials for regenerative medicine, 2019 & 2020
Fig. 19 Total global regenerative medicine financing, USD Billion, 2020
Fig. 20 Prevalence of chronic diseases in the U.S.
Fig. 21 Regenerative medicine market restraint impact
Fig. 22 Challenges in gene therapy arena by degree of difficulty to overcome
Fig. 23 Penetration & growth prospect mapping for therapeutic category, 2021
Fig. 24 Troubleshooting the challenges of implementing new reimbursement models pertaining to regenerative medicine
Fig. 25 Reimbursement models pertaining to regenerative medicine
Fig. 26 Operational entities associated with Alliance for regenerative medicine: Technology ove
Fig. 27 Inpatient vs. outpatient costs associated with CAR-T cell therapy
Fig. 28 Regenerative medicine: Market influencers
Fig. 29 SWOT analysis, by factor (Political & legal, economic, and technological)
Fig. 30 Porter’s Five Forces Analysis
Fig. 31 Strategy mapping
Fig. 32 Total M&A upfront payments in regenerative medicine space, by year
Fig. 33 Regenerative medicines market: Business model
Fig. 34 Registered cell therapy contract manufacturing organization (CMO) locations in the EU,
Fig. 35 Marketing channels
Fig. 36 Recent developments by key market participants
Fig. 37 Impact analysis of strategic moves employed by key market participants
Fig. 38 Company/competition categorization
Fig. 39 Key customers
Fig. 40 Key company market position analysis, 2022
Fig. 41 Top regional players: Regenerative medicine market
Fig. 42 Regenerative medicine market: Competitive dashboard analysis
Fig. 43 Regenerative medicine market: Product outlook and key takeaways
Fig. 44 Regenerative medicine market: Product movement analysis (USD Million)
Fig. 45 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
Fig. 46 Global primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 47 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 48 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 49 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 50 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 51 Global other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 52 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 53 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 54 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 55 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 56 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
Fig. 57 Global gene therapies market, 2018 - 2030 (USD Million)
Fig. 58 Global regenerative medicines tools, 2018 - 2030 (USD Million)
Fig. 59 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
Fig. 60 Global regenerative medicine services market, 2018 - 2030 (USD Million)
Fig. 61 Regenerative medicine market: Therapeutic category outlook and key takeaways
Fig. 62 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
Fig. 63 Global dermatological therapeutics category market, 2018 - 2030 (USD Million)
Fig. 64 Global musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
Fig. 65 Global immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
Fig. 66 Global oncology therapeutics category market, 2018 - 2030 (USD Million)
Fig. 67 Global cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
Fig. 68 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
Fig. 69 Global other therapeutics category market, 2018 - 2030 (USD Million)
Fig. 70 Regional outlook and key takeaways
Fig. 71 Regenerative medicine market: Regional movement analysis
Fig. 72 North America regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 U.S. regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Canada regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Europe regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Germany regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 U.K. regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 France regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Spain regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Italy regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Sweden regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Denmark regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Norway regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Asia-Pacific regenerative medicine market estimates and forecast, 2016-2027 (USD Millio
Fig. 85 Japan regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 China regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 India regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Australia regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 South Korea regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 Thailand regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Latin America regenerative medicine market estimates and forecast, 2016-2027 (USD Milli
Fig. 92 Brazil regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Mexico regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Argentina regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 MEA regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 96 South Africa regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Saudi Arabia regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 UAE regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Kuwait regenerative medicine market estimates and forecast, 2018 - 2030 (USD Million)
